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Position for Sapien XT and CoreValve
During a Valve-in-Valve ProcedureVinnie N. Bapat, MD, Rizwan Q. Attia, MRCS, Fortunata Condemi, MD,
Ravi Visagan, MBBS, Maya Guthrie, BSC, Shelina Sunni, BSC, Martyn Thomas, MD
London, United KingdomObjectives This study sought to provide a guide to the ﬂuoroscopic appearances of various valve-in-
valve (VIV) combinations by deploying a transcatheter heart valve (THV) within a degenerated surgical
heart valve (SHV) in an ideal position.
Background VIV procedures are being increasingly performed with substantial experience acquired in
treating degenerated SHV in the aortic position with Sapien/Sapien XT (Edwards Lifesciences Ltd.,
Irvine, California) and CoreValve/Evolute (Medtronic Inc., Minneapolis, Minnesota) valves. Although less
invasive than conventional surgery, securing the THV in an optimal position within the SHV determines
the success of this novel treatment.
Methods For VIV implantation, we selected appropriate Sapien XT and CoreValve/Evolute sizes
depending on the internal diameter of the SHV. Implantation was performed in vitro. In case of the
Sapien XT valve, it was deployed 4 to 5 mm below the sewing ring of the SHV, whereas the CoreValve/
Evolute was deployed 5 mm below the level of the sewing ring. Photographs and ﬂuoroscopic images
of the various VIV combinations were obtained in side proﬁle to study the ideal position and end-on
proﬁle to study the circularity of the THV.
Results Fluoroscopic images obtained in side proﬁle highlighted the differences in various VIV
combinations, as all SHV are unique in their ﬂuoroscopic appearances. Also, all THV implants in various
VIV combinations achieved a nearly circular shape.
Conclusions To achieve an optimal result when considering VIV, it is important to be familiar with the
structure and ﬂuoroscopic appearances of the failed SHV, the THV used, and their combination.
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Abbreviations
and Acronyms
SHV = surgical heart
valve
THV = transcatheter heart
valve
VIV = valve-in-valve
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 1 1 , 2 0 1 3 Bapat et al.
N O V E M B E R 2 0 1 3 : 1 1 8 6 – 9 4 Fluoroscopic Guide to Valve-in-Valve
1187Transcatheter aortic valve implantation has established itself
as an accepted therapy for inoperable and high-risk patients
with calciﬁc aortic stenosis (1). Clinical need has led to the
use of this technology in a variety of indications, such as in the
treatment of a degenerated bioprosthetic surgical heart valve
(SHV) (2). Multiple reports of valve-in-valve (VIV) proce-
dures have appeared in the literature during the last 2 years
with substantial experience acquired in treating a degenerated
SHV in the aortic position with 2 transcatheter heart valve
(THV) devices currently available on the marketdSapien/
Sapien XT (Edwards Lifesciences Ltd., Irvine, California)
and CoreValve/Evolute (Medtronic Inc., Minneapolis,
Minnesota) (2–8). Initial experience, although small, of VIV
procedures for degenerated SHV in mitral, tricuspid, and
pulmonary positions has also been reported (9–11).
This novel treatment appears promising as it is less
invasive and provides a secure and nearly circular landing
zone for the THV. Securing the THV in an optimal position
within the SHV and choosing the right size of the THV
determines the immediate and long-term success of this novel
treatment. A suboptimal position can be fraught with
complications such as embolization, suboptimal function, or
regurgitation (12). Understanding the structure and ﬂuoro-
scopic appearances of various SHV and both THV helps
achieve an optimal result during a VIV procedure. In this
paper, we discuss the ﬂuoroscopic relationship between
various VIV combinations and provide a ﬂuoroscopic guide to
an optimal positioning of the THV within various commer-
cially available SHV.We also examine whether supra-annular
position of the CoreValve can be maintained when implanted
within a bioprosthetic SHV and whether circularity of the
THV is maintained after a VIV implantation.Methods
SHV. Various SHV were obtained from the different
manufacturers (Table 1). Most SHV are manufactured andTable 1. Surgical Heart Valve Characteristics
Manufacturer Valve Model
Edwards Lifesciences Carpentier-Edwards Perimount 2700 and 2725
Carpentier-Edwards Perimount Magna and Magna Ease
Carpentier-Edwards Aortic Porcine bioprosthesis
Carpentier-Edwards SupraAnnular (SAV) Aortic Porcine biop
Medtronic Inc. Mosaic Tissue valve
Hancock II Tissue valve
St. Jude Medical Epic (Biocor) valve
Epic Supra (Biocor Supra) valve
Trifecta valve
Sorin Mitroﬂow
Soprano Armonia
IA ¼ intra-annular; SA ¼ supra-annular,marketed as a single model across the globe, but the Peri-
mount SHV (Edwards Lifesciences Ltd.) is available in 2
models that are different in their ﬂuoroscopic appearance;
model 2700 is used in the United States, and model 2725 is
used in the rest of the world (Fig. 1).
THV. SAPIEN XT. Three sizesd23, 26, and 29dare
commercially available in Europe. In addition, size 20 is
available in Canada and Japan. Details of the stent height
and diameter are provided in Table 2. The stent material is
cobalt chromium alloy. Sizes 20 to 26 have 2 rows of metal
“cells” of which the bottom row is covered with cloth
(Fig. 2A), and the size 29 has 3 rows of which the lower 2
are covered with cloth (Fig. 2B). The bovine pericardial
leaﬂets are sutured to the stent frame. This is visible exter-
nally by a green suture line (Figs. 2A and 2B), the level of
which can be identiﬁed ﬂuoroscopically (Fig. 2C).COREVALVE AND EVOLUTE. CoreValve sizes 26, 29, and 31
and Evolute size 23 are available commercially (Fig. 3). The
stent height and diameter for all sizes is provided in Table 2.
Each stent has 3 parts: inﬂow; waist; and outﬂow. The inﬂow
of these valves is covered with porcine pericardium and is the
part that essentially stays in the left ventricular outﬂow tract.
The waist is where the porcine
pericardial leaﬂets are sutured to
the stent. CoreValve and Evolute
metal frames have joints referred
to as “nodes,” which help in
identifying the actual valve
structure under ﬂuoroscopy
(Fig. 3A and 3B). The nadir of
the leaﬂets corresponds to the
third node from the base of the valve (Fig. 3C). The outﬂow
remains in the ascending aorta and helps stabilize the device.
VIV implantation. For VIV implantation, we selected the
appropriate Sapien XT and CoreValve/Evolute sizes
depending on the internal diameter of the SHV.Referred to as Type Radio-Opaque Part
Perimount 2700 and
Perimount 2725
IA Stent
Magna SA Stent
CE Porcine IA Stent
rosthesis CE SAV Porcine SA Stent
Mosaic SA Tip of stent
Hancock II SA Sewing ring
Epic IA Sewing ring
Epic Supra SA Sewing ring
Trifecta SA Stent
Mitroﬂow SA Sewing ring
Soprano SA Sewing ring
Figure 1. Two Models of Perimount Heart Valve
(A) Perimount 2700 and its ﬂuoroscopic appearance. (B) Perimount 2725 and its ﬂuoroscopic appearance.
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1188Implantation was performed in vitro. The Sapien XT valve
was crimped using a dedicated crimper and delivery system
and deployed inside a SHV to achieve a secure ﬁxation. A
secure implant was achieved uniformly across various SHV
types by implanting the Sapien XT valve 4 to 5 mm below
the sewing ring of the SHV, unlike a 50-50 placement of
Sapien XT needed in the native calciﬁed aortic valve.
For a CoreValve/Evolute, the recommended implant
depth in the treatment of native aortic stenosis is 5 mm
below the annular plane; this was maintained for VIV
implants in vitro also. A suitable size CoreValve/Evolute was
crimped in cold saline and then deployed 5 mm below the
level of the sewing ring in a hot water bath with temperature
>37C.
Photographs and ﬂuoroscopic images of the various VIV
combinations were obtained in side proﬁle, which provided
the basis of an ideal implant position for various VIV
combinations and end on, which provided an idea about the
circularity of the THV after implantation (Fig. 4).Table 2. Transcatheter Heart Valve Characteristics
THV Valve Type Valve Size
Sapien XT 20 23 26 29
Height, mm 14 14 17 19
Diameter, mm 20 23 26 29
CoreValve/Evolute 23 26 29 31
Height, mm 55 55 53 31
Diameter, mm 23.3 26 29 52
THV ¼ transcatheter heart valve.Results
Ideal deployment. Fluoroscopic images obtained in side
proﬁle highlighted the differences in various VIV combi-
nations. This is because all SHV are unique in their ﬂuo-
roscopic appearances, and the relationship between the
radio-opaque markers in a given SHV and the level of its
sewing ring also varies. This difference was particularly
obvious when a particular SHV model was available in
intra-annular and supra-annular designs (Figs. 4A and 4C to
4E).
Circularity. All THV implants achieved near circularity in
various VIV combinations (Figs. 4E and 4F).Discussion
Importance of an ideal position. As in the treatment of
a native calciﬁed aortic valve, an ideal placement of a THV is
important when performing a VIV procedure. Due to
differences in their design, both THV will present with
unique problems when implanted in a suboptimal position.
If implanted too high, both can result in embolization and/
or coronary obstruction (12,13). A low implantation in the
case of the Sapien XT valve can result in aortic regurgitation
from a leak through the open cells due to its relatively shorter
covered portion; in addition, it may not cover the degen-
erated SHV leaﬂets fully, which may then interfere with its
function (12). In the case of CoreValve/Evolute, a low
implantation can lead to loss of the supra-annular function
of its leaﬂets and incomplete expansion of the waist, which
Figure 2. Sapien XT Valve Features
(A) Size 26 Sapien XT made of 2 rows of metal cells (1 and 2). (B) Size 29 Sapien XT made of 3 rows of metal cells (1, 2, and 3). (C) Sapien XT size 29 under ﬂuoroscopy.
Arrows point to the level of the nadir of the leaﬂets. Row 1 is not covered by the fabric across all sizes.
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1189may result in suboptimal valve function. It can also interfere
with mitral valve function (14).
Thus, an ideal placement of a THV in SHV can be
deﬁned as a placement where it is securely ﬁxed to prevent
an embolization but has its uncovered portion above the
sewing ring of the bioprosthetic valve and has covered the
degenerated bioprosthetic leaﬂets without causing coro-
nary obstruction. As the VIV procedure is predominantly
performed under ﬂuoroscopic guidance, understanding
the relationship between the actual structure of the THV
and the SHV and their radio-opaque components is
important.
Bioprostheses design and its relevance to ideal positioning.
SHV have 3 components: the 3 leaﬂets; the stent frame;
and a sewing ring that is outside the stent frame (15). During
open-heart surgery, the sewing ring of a SHV is sutured
to the aortic valve annulus after excision of the leaﬂets.
This provides the narrowest and most secure plane. DuringFigure 3. Evolute and CoreValve Features
(A) Evolute size 23; (B) CoreValve size 29; and (C) CoreValve size 29 under ﬂuorosco
of the pericardial leaﬂets.a VIV procedure, a correct size THV should be deployed
at least 4 to 5 mm below this plane to achieve a secure
ﬁxation.
A few SHV are manufactured as intra-annular and supra-
annular designs, which look very similar under ﬂuoroscopy;
for example, CE Porcine and CE SAV Porcine (Edwards
Lifesciences), Perimount and Perimount Magna, and Epic
and Epic Supra (St. Jude Medical, St. Paul, Minnesota)
(15). To identify the level of the sewing ring under ﬂuo-
roscopy, it is important to understand the difference between
intra-annular and supra-annular designs of a SHV. Essen-
tially, an intra-annular design has the sewing ring 3 to 5 mm
above the bottom of the stent frame, whereas in the supra-
annular design, the sewing ring and the bottom of the stent
frame are at the same level (Figs. 5A and 5B). This is not
important when the sewing ring itself is radio-opaque as in
the Epic and Epic Supra (Figs. 4H and 4I) but assumes
importance when the stent rather than sewing ring is visiblepy. The arrows point to the third node, which corresponds to the nadir
Figure 4. Valve-in-Valve Combinations
Various valve-in-valve combinations for appropriate sized Sapien and CoreValve/Evolute within various surgical heart valves. Each ﬁgure (A) to (L) has 6 panels: a and
b show the side proﬁle of the implanted CoreValve in an ideal position; c and d show the Sapien XT in an ideal position; e shows the end-on ﬂuoroscopic view of the
Sapien XT after implantation; and f shows the end-on ﬂuoroscopic view of the CoreValve after implantation to assess their circularity. (A) Perimount 2725;
(B) Perimount 2700; (C) Magna; (D) CE; (E) CE SAV Porcine; (F) Trifecta (St. Jude Medical); (G) Hancock II (Medtronic); (H) Epic; (I) Epic supra; (J) Soprano (Sorin, Milan,
Italy); (K) Mitroﬂow (Sorin); (L) Mosaic.
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1190under ﬂuoroscopy as in CE Porcine and CE SAV Porcine
(Figs. 4D and 4E).
Thus, in Perimount and Magna (Figs. 4A and 4C) or CE
Porcine and CE SAV Porcine (Figs. 4D and 4E), the level
at which the THV is deployed for secure ﬁxation varies asthe sewing ring is at different levels. Therefore, in a degen-
erated CE Porcine and Perimount (intra-annular designs),
the sewing ring is already 5 mm above the inﬂow, hence the
bottom of the THV should be deployed in line with the
bottom of the radio-opaque markers of these valves
Figure 4. Continued
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1191(Figs. 5C and 5E). However, if these were CE SAV Porcine
or Magna (supra-annular designs), where the sewing ring is
in line with the bottom of the inﬂow, the THV should be
deployed 5 mm below the radio-opaque markers of these
valves for secure ﬁxation (Figs. 5D and 5F).
A few SHV such as Mosaic (Medtronic) present a unique
challenge as they do not have a marker to identify the levelof the sewing ring. Although a balloon aortic valvuloplasty
can be performed to deﬁne the waist, which corresponds to
the level of the sewing ring, it is not desirable and is
unnecessary as it may lead to leaﬂet tear or particulate
embolization. The best way to ensure an ideal placement of
the transcatheter device 4 to 5 mm below the sewing ring is
to deploy the Sapien XT valve in such a manner that the
Figure 4. Continued
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1192top of the valve lies just below the radio-opaque eyelets
(Fig. 4L) and the CoreValve/Evolute such that the fourth
node is level with the eyelets (Fig. 4L). We have quantiﬁed
this in all suitable combinations of Mosaic and Sapien XT/
CoreValve/Evolute.
Circularity. Majority of the SHV when implanted surgically
are nearly circular. If the leaﬂets are thickened and calciﬁed
irregularly, it can inﬂuence the ﬁnal circularity of the THV.We obtained end-on ﬂuoroscopic views of both Sapien and
CoreValve combinations to check the degree of circularity.
In all cases, near-circularity was achievable for both the valves
across all types of VIV combinations. Examples of various
combinations are demonstrated in Figures 4E and 4F.
Supra-annular position of CoreValve/Evolute. When ideally
placed, the supra-annular position of CoreValve/Evolute
was maintained across all VIV combinations. This was
Figure 4. Continued
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1193conﬁrmed by identifying the position of the third node from
the base (which corresponds to the nadir of leaﬂets) in
relation to the sewing ring of SHV (Fig. 4B).
It also becomes clear that if the CoreValve/Evolute
is implanted deeper, then it may lose its supra-annular
position. When implanted in an ideal position, whether asupra-annular position translates into supra-annular func-
tion needs to be quantiﬁed with ﬂow studies, as it might
depend on the degree of splaying of the stent posts of the
SHV. This, in turn, depends on the radial strength of the
CoreValve/Evolute and the resistance offered by stent posts,
which varies in all SHV.
Figure 5. Intra-Annular and Supra-Annular Design and Its Implication in a Valve-in-Valve Procedure
Differences in design of intra-annular and supra-annular bioprostheses and their relevance in valve-in-valve procedures. (A) Intra-annular design: sewing ring is 4 to
5 mm above the base of the SHV stent. (B) Supra-annular design: sewing ring and the base of the stent are at the same level. (C) Sapien XT implanted in an intra-
annular design. (D) Sapien XT implanted in a supra-annular design. (E) CoreValve implanted in an intra-annular design. (F) CoreValve implanted in a supra-annular
design.
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1194Conclusions
We, therefore, conclude that an understanding of the ﬂuo-
roscopic appearances of SHV, THV, and their combinations
provides an excellent guide for a VIV procedure. This is
essential to avoid embolization due to high placement and
suboptimal function due to low placement of the THV.
Circularity of the THV is also maintained across all VIV
combinations. Supra-annular position of a CoreValve/
Evolute is also achieved when placed in an ideal position but
needs further testing to evaluate actual beneﬁt.
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